Aardvark Therapeutics (AARD) vs Inovio Pharmaceuticals (INO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Inovio Pharmaceuticals (INO) has outperformed Aardvark Therapeutics (AARD) over the past year, losing 57.4% versus a loss of 72.5%. Inovio Pharmaceuticals is the larger company by market cap ($113.2 million vs $103.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AARD | INO |
|---|---|---|
| Share price | $4.74 | $1.10 |
| Market cap | $103.73M | $113.22M |
| 1-day change | +0.64% | +0.46% |
| YTD return | -64.11% | -37.36% |
| 1-year return | -72.50% | -57.42% |
| 5-year return | — | -98.71% |
| EPS (TTM) | $-3.21 | $-0.90 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.06 | $2.72 |
| 52-week low | $3.35 | $0.56 |
| Distance from 52-week high | -72.21% | -59.74% |
| Analyst consensus | buy | none |
| Avg. price target upside | +134.39% | +189.50% |
| Average volume | 208.11K | 3.86M |
| Shares outstanding | 21.88M | 103.40M |
| Employees | 28 | 112 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INO has outperformed AARD by 15.1 percentage points over the past year.
About Aardvark Therapeutics
AARD stock →Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
About Inovio Pharmaceuticals
INO stock →Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.
Health Care · Biotechnology: Pharmaceutical Preparations · 112 employees
AARD vs INO FAQ
Which is bigger, Aardvark Therapeutics or Inovio Pharmaceuticals?
Inovio Pharmaceuticals (INO) is larger, with a market capitalization of $113.22M compared with $103.73M for Aardvark Therapeutics (AARD).
Which stock has performed better over the past year, AARD or INO?
INO returned -57.42% over the past 12 months, compared with -72.50% for AARD (price return, excluding dividends). Past performance does not predict future results.
Are Aardvark Therapeutics and Inovio Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.